Manufacturer Solutions
Creating Sustainability & Longevity for Biosimilars
At AmerisourceBergen, we believe in the promise of biosimilars to deliver cost savings across healthcare. We also understand the potential hurdles these unique products will face. That's why we offer solutions for increasing access to and confidence in these emerging therapies.
For manufacturers
Distribution & commercialization services
Our experts can help you devise channel strategies and tailored solutions for access and uptake. And, we have market-leading reach into the sites of care where patients are being treated with biosimilars.
For providers
Education & reimbursement support
Our market-leading GPOs connect physicians and manufacturers for unrivaled purchasing power and education. Plus, field reimbursement support helps practices navigate payment for these new products.
For patients
Impacting access, affordability & adherence
Our patient assistance program (PAP) models and adherence services are tailored to your product and patient needs and integrate seamlessly with our reimbursement and co-pay services.
Our relationships span:
Nearly
100%
of U.S. hospitals and health systems
Oncology
60%
of U.S. community oncology market
Nephrology
90%
of U.S. renal market
Rheumatology
2,100
provider sites
Ophthalmology
4,200
provider sites
Related Insights
New Podcast Episode - Biosimilars: Patents, policy, and reimbursement
In the inaugural episode of the AmerisourceBergen Insights podcast, we’re looking at the biosimilars market with Sean McGowan, Senior Director of Biosimilars at AmerisourceBergen. Sean will be joined by David Senior and Steve Miller to discuss the policy and reimbursement issues that impact our customers and the overall growth of biosimilars.
The changing Biosimilars landscape
COVID-19 changed the way physician practices and health systems interacted with patients. The pandemic has presented opportunities for greater engagement with customers who are building a strategy around adoption and cost savings.
It has been a successful year, and 2021 looks just as promising. Sean McGowan anticipates new manufacturers and a second wave of products into existing biosimilar markets.
Physician Q&A: How to Boost Confidence in Biosimilars
Biosimilars have the potential to reduce healthcare costs in the United States — but only if the market grows. Dr. Kashyap Patel, Medical Director at Carolina Blood and Cancer Care, provides perspective on how manufacturers can help deliver on the promise of cost savings by improving physician confidence in biosimilars.
In the News